申请人:Hartmann Rolf
公开号:US20140155407A1
公开(公告)日:2014-06-05
The present invention relates to compounds which selectively inhibit CYP11B1. Preferably, the compounds of the present invention do not substantially inhibit CYP11B2. Moreover, the compounds of the present invention do not substantially inhibit CYP17 and/or CYP19, either. Amongst other applications of the compounds of the present invention, they can be used for the treatment of Cushing's syndrome or metabolic disease.
本发明涉及一种选择性抑制CYP11B1的化合物。优选地,本发明的化合物不会显著抑制CYP11B2。此外,本发明的化合物也不会显著抑制CYP17和/或CYP19。在本发明化合物的其他应用中,它们可用于治疗库欣综合征或代谢疾病。